<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Drug Delivery</title>
	<atom:link href="http://www.stockbloghub.com/category/drug-delivery/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 16 May 2012 17:53:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALKS) Risk-Reward Balanced at Alkermes</title>
		<link>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426</link>
		<comments>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426#comments</comments>
		<pubDate>Wed, 07 Mar 2012 17:19:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=94426</guid>
		<description><![CDATA[We are maintaining a Neutral rating on Alkermes (ALKS) with a target price of $18.00. Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (ELN). The merger has expanded the portfolio significantly resulting in a 185.7% increase in revenues during the quarter. The expanded portfolio caused management to increase the 2012 revenue projection. Revenues are projected in the range of $370-$400 million, up from the previous guidance of $350-$380 million. Given the expanded product portfolio, we expect the company to achieve/beat the increased guidance. Consequently, the Zacks Consensus Estimate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/07/alks-risk-reward-balanced-at-alkermes-analyst-blog/94426/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003</link>
		<comments>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003#comments</comments>
		<pubDate>Thu, 27 Oct 2011 17:24:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86003</guid>
		<description><![CDATA[Hospira Inc.&#8217;s (HSP) third quarter preliminary results were below expectations due to continued manufacturing problems at the company&#8217;s Rocky Mountain facility. The facility is expected to continue functioning below full capacity through the remainder of 2011. The additional costs for manufacturing remediation resulted in lost sales, inventory loss and lower service levels. In addition, management cut its 2011 adjusted earnings guidance to $2.95-$3.05 from $3.90-$4.00. We have slashed our 2011 earnings estimate from $3.93 to $3.01 and our 2012 estimates from $4.47 to $2.85, in line with management&#8217;s action. Moreover, the Symbiq and Plum pump issues remain matters of concern. We have, therefore, downgraded our rating on Hospira from Neutral to Underperform. HOSPIRA INC (HSP): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/27/hsp-hospira-incorporated-bear-of-the-day/86003/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387</link>
		<comments>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387#comments</comments>
		<pubDate>Thu, 01 Sep 2011 16:55:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82387</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS). Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. In August 2011, Alkermes disclosed financial results for the first quarter of fiscal 2012. Alkermes suffered a net loss (excluding special items but including stock-based compensation expense) of $0.04 per share which compared favorably with the year-ago loss of $0.14 per share. The Zacks Consensus Estimate was a loss of $0.11 per share. The narrower year-over-year loss was attributable to higher revenues recorded in the reported quarter. The lead product at Alkermes is Risperdal Consta for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/alks-alkermes-analyst-maintains-neutral-rating-on-shares/82387/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Still Underperforms</title>
		<link>http://www.stockbloghub.com/2011/07/05/pets-petmed-still-underperforms/78348</link>
		<comments>http://www.stockbloghub.com/2011/07/05/pets-petmed-still-underperforms/78348#comments</comments>
		<pubDate>Wed, 06 Jul 2011 00:15:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78348</guid>
		<description><![CDATA[Recently, we reaffirmed our Underperform recommendation on PetMed Express (PETS) with a target price of $11.00. PetMed has been reporting disappointing results over the past few quarters. Lower revenues coupled with higher operating expenses had a negative impact on margins. Moreover, the company also witnessed decline in new customers to 130,000 in the last reported quarter, down from 134,000 in the year-ago period. The average order size has declined by $4 compared to the year-ago quarter to $78 amidst economic uncertainty that forced customers to become price sensitive. PetMed also witnessed a 5% decline in new reorder sales to $9.4 million primarily due to an increase in customer acquisition costs. This is a big blow for the company as it depends on advertising for expanding its customer base. Despite general ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/pets-petmed-still-underperforms/78348/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Presents Encouraging Data</title>
		<link>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229</link>
		<comments>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229#comments</comments>
		<pubDate>Fri, 01 Jul 2011 20:31:22 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78229</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) presented encouraging top line data from an early stage study of its schizophrenia candidate ALKS 9070 (n=32).  ALKS 9070 is a once-monthly injectable extended release version of Bristol-Myer Squibb’s (BMY) schizophrenia drug Abilify (aripiprazole).  Alkermes intends to present complete data from the study at an upcoming medical conference. The double-blind, randomized, placebo-controlled 20-week study evaluated the safety, tolerability and pharmacokinetics of ALKS 9070 (once-monthly) at 3 doses in patients suffering from chronic, stable schizophrenia. Data from the study revealed that the candidate was generally well tolerated at all  doses and achieved therapeutically relevant plasma concentrations of Abilify. The pharmacokinetic profile backed the once-monthly dosing of ALKS 9070. Encouraged by the positive results, the company intends to commence a pivotal development program for the candidate by the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/alks-alkermes-presents-encouraging-data/78229/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/07/01/pets-petmed-express-bear-of-the-day-2/78157</link>
		<comments>http://www.stockbloghub.com/2011/07/01/pets-petmed-express-bear-of-the-day-2/78157#comments</comments>
		<pubDate>Fri, 01 Jul 2011 16:39:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78157</guid>
		<description><![CDATA[PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19, missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter&#8217;s $0.27. While new order sales declined on fewer new customers, revenues increased 1.2% to $50.9 million. Both gross and operating margins declined due to higher product and advertising costs. This is a big blow for the company as it depends heavily on advertising to expand its customer base. Moreover, economic uncertainty is taking a toll on the company, forcing consumers to switch to cheaper alternatives. We do not expect the situation to improve significantly in the near future. We maintain our Underperform recommendation on the stock. PETMED EXPRESS (PETS): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/01/pets-petmed-express-bear-of-the-day-2/78157/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Evenly Poised</title>
		<link>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334</link>
		<comments>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334#comments</comments>
		<pubDate>Fri, 24 Jun 2011 16:32:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77334</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alkermes, Inc. (ALKS) with a target price of $18.00. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. We are positive on Alkermes’ decision to buy  Elan Corporation’s (ELN) drug delivery unit. The deal is expected to boost Alkermes’ cash earnings immediately following its closure. The product portfolio at Alkermes will be strengthened following the merger. Alkermes currently has two marketed drugs namely Risperdal Consta and Vivitrol in its product portfolio. Risperdal Consta is marketed worldwide by Johnson &#38; Johnson (JNJ) for the treatment of schizophrenia and bipolar disorder. The drug is manufactured by Alkermes. The other approved product at Alkermes is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/alks-alkermes-evenly-poised/77334/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/05/16/pets-petmed-express-bear-of-the-day/74104</link>
		<comments>http://www.stockbloghub.com/2011/05/16/pets-petmed-express-bear-of-the-day/74104#comments</comments>
		<pubDate>Mon, 16 May 2011 15:00:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=74104</guid>
		<description><![CDATA[PetMed Express (PETS) reported a disappointing quarter with EPS of $0.19 missing the Zacks Consensus Estimate of $0.22 and the year-ago quarter&#8217;s $0.27. Both gross and operating margins declined due to higher product and advertising costs &#8212; a big blow for the company as it depends on advertising to increase its customer base. Moreover, economic uncertainty is taking a toll on the company, forcing consumers to switch to cheaper alternatives. We do no expect the situation to improve significantly in the near future. We maintain our Underperform recommendation on the stock. Over the last five years, the company&#8217;s shares have traded in a range of 13.7X to 24.8X trailing 12-month earnings. Our target price of $12.00 per share is based on 14.5X our 2012 EPS estimate of $0.83. PETMED EXPRESS ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/16/pets-petmed-express-bear-of-the-day/74104/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Stock Market News for May 10, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711</link>
		<comments>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711#comments</comments>
		<pubDate>Tue, 10 May 2011 16:55:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[Baker Hughes Inc.]]></category>
		<category><![CDATA[BHI]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Dollar Thrifty Automotive Group Inc]]></category>
		<category><![CDATA[DTG]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Frontier Oil Corporation]]></category>
		<category><![CDATA[FTO]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[Hertz Global Holdings Inc.]]></category>
		<category><![CDATA[HOC]]></category>
		<category><![CDATA[Holly Corporation]]></category>
		<category><![CDATA[HTZ]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[NVDA]]></category>
		<category><![CDATA[NVIDIA Corporation]]></category>
		<category><![CDATA[SGY]]></category>
		<category><![CDATA[Stone Energy Corporation]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73711</guid>
		<description><![CDATA[After suffering a slump last week, commodities made a strong comeback yesterday and lifted the benchmarks higher. Energy shares joined in on the uptrend as crude prices once again rose above $100 per barrel. Meanwhile fresh worries about Greece’s credit ratings partially limited gains. The Dow Jones Industrial Average (DJIA) rose 0.4% to close at 12,684.68. The Standard &#38; Poor 500 (S&#38;P 500) gained 0.5% and finished the day at 1,346.29. The Nasdaq Composite Index increased 0.6% to settle at 2,843.25. The fear-gauge CBOE Volatility Index dropped down to almost 17. On the New York Stock Exchange, composite volumes were low, at only 3 billion shares. For every couple of stocks that gained, one stock moved down. Markets witnessed a massive sell off of commodities last week as investors chose ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/10/alks-stock-market-news-for-may-10-2011-market-news/73711/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermesto Buy Elan Unit for $960 Million</title>
		<link>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637</link>
		<comments>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637#comments</comments>
		<pubDate>Mon, 09 May 2011 22:55:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACOR]]></category>
		<category><![CDATA[Acorda Therapeutics Inc]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[HBC]]></category>
		<category><![CDATA[HSBC HLDGS PLC ADS]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73637</guid>
		<description><![CDATA[Recently, Alkermes, Inc. (ALKS) inked a deal with Elan Corporation (ELN) to buy the latter’s Elan Drug Technologies (EDT) segment. The EDT segment is the drug delivery unit of Elan. The merger, expected to close in the third quarter of calendar 2011, is worth approximately $960 million. The merged entity will be known as Alkermes plc and will be headquartered in Dublin, Ireland. The deal, expected to boost Alkermes’ cash earnings immediately following its closure, has been cleared by the board of directors of both companies. Morgan Stanley &#38; Co. (MS) and HSBC (HBC) have agreed to finance up to $450 million of the deal through term loans to Alkermes. Per the terms of the deal, Alkermes will make a cash payment of $500 million apart from giving Elan 31.9 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/alks-alkermesto-buy-elan-unit-for-960-million/73637/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Earnings Beat The Street &#8211; Backs Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495</link>
		<comments>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495#comments</comments>
		<pubDate>Tue, 03 May 2011 19:27:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[APAC]]></category>
		<category><![CDATA[APAC Customer Services Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72495</guid>
		<description><![CDATA[Hospira Inc. (HSP) reported earnings per share of 93 cents for the first quarter of 2011, well above the Zacks Consensus Estimate of 79 cents. Earnings benefited from strong US sales of the generic version of Sanofi Aventis’ (SNY) cancer drug Taxotere which was launched in March 2011. Results were however 1 cent below the year-earlier earnings of 94 cents due to difficult year-over-year comparisons. Earnings in the prior-year quarter were boosted by strong margin contribution from US sales of Hospira’s generic version of Sanofi’s Eloxatin (oxaliplatin) which has been temporarily discontinued. Higher research and development expenses also affected earnings in the quarter. First quarter revenues of $1 billion were almost flat year over year. Total revenues beat the Zacks Consensus Estimate of $941 million. The top line was boosted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/hsp-hospira-earnings-beat-the-street-backs-outlook/72495/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Company News for April 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757</link>
		<comments>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757#comments</comments>
		<pubDate>Mon, 18 Apr 2011 19:25:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BRNC]]></category>
		<category><![CDATA[Bronco Drilling Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Finish Line Inc.]]></category>
		<category><![CDATA[FINL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[ROSE]]></category>
		<category><![CDATA[Rosetta Resources Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71757</guid>
		<description><![CDATA[• Chesapeake Energy Corp&#8217;s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase price represents a 24% premium over Bronco’s average 90-day closing price • A report from Bloomberg cited that eBay Inc. (NASDAQ:EBAY) gains in its bid to grow its business in China • Share prices of French chip company Sequans Communications (NYSE:SQNS) fell 17.5% to close at $8.25 on its first day of trading on the New York Stock Exchange • Share prices of Bank of America (NYSE:BAC) fell 2.36% after the banking giant reported a 36% decline in first-quarter profits as the foreclosures crisis continued to squeeze its home loan business. Bank of America is the largest U.S. bank by assets • Shares of Merck (NYSE:MRK) rose 1.92% to $34.51 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes 2010 Second Quarter Revenues Rise &#8211; View Lowered</title>
		<link>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507</link>
		<comments>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507#comments</comments>
		<pubDate>Thu, 25 Nov 2010 06:59:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=58507</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) second quarter fiscal 2011 net loss (excluding special items) of 6 cents per share compared unfavorably with the year-ago loss of 5 cents per share. The Zacks Consensus Estimate was a loss of 15 cents per share. The narrower-than-expected loss was attributable to the higher revenues recorded in the quarter. Total revenues for the reported quarter climbed 2% to $49.2 million. The increase was primarily attributable to higher manufacturing, royalty and sales revenues. Revenues for the reported quarter surpassed the Zacks Consensus Estimate of $43 million. We note that Alkermes derives the bulk of its revenue from schizophrenia drug Risperdal Consta. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes generated $32.6 million from manufacturing the drug in the reported quarter ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/24/alks-alkermes-2010-second-quarter-revenues-rise-view-lowered/58507/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) Elan Quarterly Report Matches Earnings Estimates</title>
		<link>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476</link>
		<comments>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476#comments</comments>
		<pubDate>Wed, 03 Nov 2010 15:12:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=57476</guid>
		<description><![CDATA[Elan Corporation plc (ELN) reported loss per share of 7 cents for the third quarter of 2010, in line with the Zacks Consensus Estimate but way below the year-ago earnings of 11 cents per share. The year-ago quarter saw Elan recording a divestment gain of $107.7 million, which is primarily the reason for the substantial year-over-year decline in earnings. On an adjusted basis, the company reported a loss of 5 cents per share, an improvement from a loss of 11 cents per share in the third quarter of 2009. Revenues Quarterly revenues declined 2% year over year to $281.4 million and also missed the Zacks Consensus Estimate of $298 million. Elan operates through two segments – BioNeurology and Elan Drug Technologies (EDT). Revenues from the BioNeurology segment went up 0.2% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/03/eln-elan-quarterly-report-matches-earnings-estimates/57476/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Vivitrol Earns US Food and Drug Administration Clearance</title>
		<link>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320</link>
		<comments>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320#comments</comments>
		<pubDate>Mon, 18 Oct 2010 03:20:42 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=55320</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) received a boost when the US Food and Drug Administration (FDA) cleared its drug Vivitrol (naltrexone for extended-release injectable suspension) for the prevention of relapse to opioid dependence after opioid detoxification. Opioid dependence refers to a chronic ailment of the brain. The approval of Vivitrol, already available for the treatment of alcohol dependence for which it gained FDA approval in 2006, for the additional indication does not surprise us. Last month, an advisory panel of the FDA had recommended the approval of Vivitrol for treating opioid dependence. The FDA’s Psychopharmacologic Drugs Advisory Committee voted 12-1 in favor of approving Vivitrol for the additional indication. We remind investors that the supplemental New Drug Application (sNDA), seeking to expand Vivitrol’s label, was submitted in April 2010. The application was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/17/alks-alkermes-vivitrol-earns-us-food-and-drug-administration-clearance/55320/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day-2/48273</link>
		<comments>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day-2/48273#comments</comments>
		<pubDate>Wed, 18 Aug 2010 18:29:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48273</guid>
		<description><![CDATA[PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter&#8217;s $0.36. The company witnessed a decline in revenues due to a lack of television remnant space availability at affordable rates. Moreover, both gross and operating margins declined during the quarter driven by increase in higher product costs and higher advertising cost to acquire a new customer. Economic uncertainty is taking a toll on the company, forcing consumers to switch to cheaper alternatives. We do no expect the situation to improve significantly in the near future. On account of these factors we have lowered our estimates and downgraded the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day-2/48273/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express Incorporated &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day/48264</link>
		<comments>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day/48264#comments</comments>
		<pubDate>Wed, 18 Aug 2010 14:03:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=48264</guid>
		<description><![CDATA[PetMed Express, Inc. (PETS) reported first-quarter fiscal 2011 EPS of $0.32, way below the Zacks Consensus Estimate of $0.38 and the year-ago quarter&#8217;s $0.36. The company witnessed a decline in revenues due to a lack of television remnant space availability at affordable rates. Moreover, both gross and operating margins declined during the quarter driven by increase in higher product costs and higher advertising cost to acquire a new customer. Economic uncertainty is taking a toll on the company, forcing consumers to switch to cheaper alternatives. We do no expect the situation to improve significantly in the near future. On account of these factors we have lowered our estimates and downgraded the stock to Underperform. Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/18/pets-petmed-express-incorporated-bear-of-the-day/48264/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Earnings Report Shows Revenues Dipped</title>
		<link>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206</link>
		<comments>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206#comments</comments>
		<pubDate>Tue, 10 Aug 2010 17:40:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=47206</guid>
		<description><![CDATA[Alkermes Inc.’s (ALKS) first-quarter fiscal 2011 net loss of  14 cents per share compared unfavorably with the year-ago loss of 2 cents per share. The Zacks Consensus Estimate was a loss of 14 cents per share. Quarterly Results Total revenues for the reported quarter declined 11% to $42.3 million. The decline was primarily attributable to lower manufacturing revenues related to the schizophrenia drug Risperdal Consta, which is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes.  Revenues were also marginally short of the Zacks Consensus Revenue Estimate of $43 million. Manufacturing revenues slipped 7% in the reported quarter to $26.9 million. Manufacturing revenues included $26.3 million from Risperdal Consta. Manufacturing revenues also included $0.6 million related to the manufacture of polymer for Byetta once-weekly (proposed trade name: Bydureon). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/10/alks-alkermes-earnings-report-shows-revenues-dipped/47206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Second Quarter 2010 Earnings Preview</title>
		<link>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895</link>
		<comments>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895#comments</comments>
		<pubDate>Mon, 02 Aug 2010 21:52:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Carefusion Corporation]]></category>
		<category><![CDATA[CFN]]></category>
		<category><![CDATA[DRRX]]></category>
		<category><![CDATA[Durect Corporation]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=44895</guid>
		<description><![CDATA[Hospira Inc. (HSP) is scheduled to report its second quarter 2010 results on Wednesday, July 28, before the opening bell. The Zacks Consensus Estimate for the quarter is earnings of 79 cents per share (with an upside of 2.53%), compared with earnings of 73 cents per share in the year-earlier period. The Zacks Consensus Estimate for second-quarter revenue is $1,006 million as against $957 million reported in the year-ago quarter. First-Quarter Recap Hospira Inc.’s first-quarter fiscal 2010 earnings (excluding special items) of 94 cents per share handsomely beat the Zacks Consensus Estimate of 72 cents and the year-ago earnings of 60 cents. On a reported basis, the company earned 84 cents per share, down 18.4% from the year-ago earnings. Revenues for the quarter climbed 17.2% year over year to $1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/02/hsp-hospira-second-quarter-2010-earnings-preview/44895/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes, Amylin Pharmaceuticals, and Eli Lilly See Encouraging Data on Diabetes Candidate Bydureon</title>
		<link>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922</link>
		<comments>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922#comments</comments>
		<pubDate>Tue, 29 Jun 2010 18:02:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41922</guid>
		<description><![CDATA[Recently Alkermes Inc. (ALKS), Amylin Pharmaceuticals Inc. (AMLN) and Eli Lilly &#38; Co. (LLY), the co-developers of type II diabetes candidate Bydureon (exenatide once weekly), presented pooled safety data on the candidate. The companies presented the data at the 70th Annual Scientific Sessions of the American Diabetes Association held in Orlando. The data came from an analysis of the results of three randomized, double-blind studies, which revealed that Bydureon was well tolerated. The studies involved patients treated with either Bydureon (n=541) or other diabetes treatments such as Merck’s (MRK) Januvia, Takeda’s Actos or Sanofi-Aventis’ (SNY) Lantus (n=554). The number of patients opting out of the studies due to serious adverse events was low. Severe hypersensitivity reactions such as serious skin reactions or anaphylaxis were not observed in any of the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/29/alks-alkermes-amylin-pharmaceuticals-and-eli-lilly-see-encouraging-data-on-diabetes-candidate-bydureon/41922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Extends Javelin Pharmaceuticals Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865</link>
		<comments>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865#comments</comments>
		<pubDate>Tue, 25 May 2010 03:25:11 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[JAV]]></category>
		<category><![CDATA[Javelin Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37865</guid>
		<description><![CDATA[Recently, Hospira (HSP) extended its tender offer for acquiring Javelin Pharmaceuticals (JAV). The offer, which was supposed to expire on May 18, has been extended till June 2, 2010 as all the conditions of the deal have not yet been met. Viewing the uncertainty surrounding the closure of the deal, shares of Javelin Pharma plunged subsequent to the announcement. In April 2010, Hospira announced its intention to acquire Javelin for $2.20 per share or approximately $145 million. If the deal with Hospira does not get through, it will be a major setback for Javelin. In December 2009, Myriad Pharmaceuticals (MYRX) had decided to acquire Javelin in a stock-swap deal. However, Javelin decided to terminate this agreement in April 2010. The termination has resulted in Javelin paying $4.4 million to Myriad ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/24/hsp-hospira-extends-javelin-pharmaceuticals-aquisition-offer/37865/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes&#8217; Quarterly Earnings Report Shows Revenue Dip</title>
		<link>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429</link>
		<comments>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429#comments</comments>
		<pubDate>Mon, 17 May 2010 22:27:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37429</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of 12 cents per share (excluding special items but including stock-based compensation) compared with a loss of 13 cents per share in the year-ago period; excluding the impact of the termination of  collaboration agreements with Cephalon Inc. (CEPH) and Eli Lilly &#38; Co. (LLY) but including stock-based compensation. The Zacks Consensus Estimate was a loss of 15 cents per share. Quarterly Results Total revenues for the reported quarter declined 12.3% year-over-year to $38.5 million. Manufacturing revenues for the fourth quarter of fiscal 2010 declined 8% year-over-year to $22.6 million. Royalty revenues for the quarter came in at $9.5 million. Research and development revenue under collaborative arrangements dropped to $0.4 million from $1.7 million in the year-ago quarter. The company also ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/17/alks-alkermes-quarterly-earnings-report-shows-revenue-dip/37429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DCTH) The Decade of Biotech: Two Hot Biotech Sectors and Eight Ways to Profit</title>
		<link>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446</link>
		<comments>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446#comments</comments>
		<pubDate>Thu, 29 Apr 2010 14:13:04 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AFFX]]></category>
		<category><![CDATA[Affymetrix Inc]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[Covance Inc.]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[CVD]]></category>
		<category><![CDATA[DCTH]]></category>
		<category><![CDATA[Delcath Systems Inc.]]></category>
		<category><![CDATA[Illumina Inc]]></category>
		<category><![CDATA[ILMN]]></category>
		<category><![CDATA[LIFE]]></category>
		<category><![CDATA[Life Technologies Corporation]]></category>
		<category><![CDATA[Pharmaceutical Product Development Inc]]></category>
		<category><![CDATA[PPDI]]></category>
		<category><![CDATA[SIAL]]></category>
		<category><![CDATA[Sigma-Aldrich Corporation]]></category>
		<category><![CDATA[WuXi PharmaTech (Cayman) Inc]]></category>
		<category><![CDATA[WX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=35446</guid>
		<description><![CDATA[I expect the 2010s to be the “Decade of Biotech.” In 2020, we’ll look back at the past 10 years in amazement at how many medical advances were achieved. And we’ll likely snicker at some of the prehistoric methods that are currently used, equating them to when doctors used to perform lobotomies on people with mental problems. By 2020, there will be new drugs on the market and technologies developed that weren’t even dreamed about at the turn of the 21st century. New discoveries will extend life, or cure diseases that even the most forward-thinking scientists couldn’t have imagined just a short time ago. And fortunes will be made as a result. The question is: How do you grab your piece of the pie? Blasting Tumors… Bagging Profits If you’re ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/29/dcth-the-decade-of-biotech-two-hot-biotech-sectors-and-eight-ways-to-profit/35446/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Announces Intentions to Acquire Javelin Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447</link>
		<comments>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447#comments</comments>
		<pubDate>Wed, 21 Apr 2010 20:57:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[JAV]]></category>
		<category><![CDATA[Javelin Pharmaceuticals]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34447</guid>
		<description><![CDATA[Recently, Hospira (HSP) announced its intention to acquire Javelin Pharmaceuticals (JAV) for $2.20 per share or approximately $145 million. Hospira expects to initiate the tender offer for all the outstanding shares of Javelin shortly. The acquisition of Javelin will provide Hospira with access to Javelin’s lead product candidate, Dyloject, a post-operative pain management drug. The drug is awaiting approval from the US Food and Drug Administration (FDA). A final decision is likely by October 3, 2010. As a non-opioid analgesic, Dyloject scores over traditional intravenous opioids, which are associated with significant adverse events in pain management. Hospira will gain global rights to Dyloject other than in Europe, where rights are licensed to a third party. Hospira plans to market the product in the US, Canada, Latin America and the Asia-Pacific ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/21/hsp-hospira-announces-intentions-to-acquire-javelin-pharmaceuticals/34447/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Files New Drug Application For Vivitrol Expansion</title>
		<link>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706</link>
		<comments>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706#comments</comments>
		<pubDate>Wed, 14 Apr 2010 21:16:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=33706</guid>
		<description><![CDATA[Recently Alkermes, Inc. (ALKS) submitted a supplemental New Drug Application (sNDA) for Vivitrol (naltrexone for extended-release injectable suspension) to the US Food and Drug Administration (FDA) for treating opioid dependence. Opioid dependence refers to a chronic ailment of the brain. The affected individual continues to use opioids despite the damage caused by it. Vivitrol, an injectable opioid antagonist administered once-monthly, is already available as an injectable medication for alcohol dependence. The drug received FDA approval in 2006. Vivitrol was initially marketed by Cephalon (CEPH) in the US. However, Cephalon terminated its collaboration with Alkermes ever since December 1, 2008. Alkermes entered into an exclusive agreement with Cilag GmbH International, a subsidiary of Johnson &#38; Johnson (JNJ), to commercialize Vivitrol in Russia and other countries in the Commonwealth Independent States (CIS) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/14/alks-alkermes-files-new-drug-application-for-vivitrol-expansion/33706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Settles Sanofi-Aventis Patent Dispute</title>
		<link>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827</link>
		<comments>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827#comments</comments>
		<pubDate>Tue, 06 Apr 2010 04:00:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32827</guid>
		<description><![CDATA[Hospira (HSP) has reached an agreement with Sanofi-Aventis (SNY) to settle a patent dispute for the US sales of oxaliplatin injection, a generic version of Sanofi-Aventis&#8217; Eloxatin. Per the settlement, Hospira will not sell oxaliplatin injection in the US until June 30, 2010. However, the drug can be re-launched on Aug. 9, 2012. Hospira has been involved in a patent litigation with Sanofi-Aventis for the past few months. Although Hospira received a favorable decision in August 2009, the decision was later vacated. Eloxatin, meant for the treatment of advanced colorectal cancer and stage III colon cancer patients after surgery, recorded US sales of €677 million in 2009. Apart from Hospira, Sanofi settled its Eloxatin patent dispute with other generic manufacturers such as Teva Pharmaceuticals (TEVA), Fresenius Kabi and Sandoz, Novartis’ ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/hsp-hospira-settles-sanofi-aventis-patent-dispute/32827/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Pipeline Advances</title>
		<link>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359</link>
		<comments>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359#comments</comments>
		<pubDate>Fri, 19 Mar 2010 22:30:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=31359</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) initiated a multidose early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist, which has the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose early-stage trial is designed to assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37. Approximately 24 healthy volunteers will be studied for a period of one week. The study will see two dose levels of ALKS 37 being tested in sequential cohorts. This study comes after the completion of a previous single dose clinical study in healthy volunteers. In that study ALKS 37 was generally well tolerated and demonstrated low systemic exposure across ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/19/alks-alkermes-drug-pipeline-advances/31359/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BVF) Biovail and Acadia Pharmaceuticals Continue Forward with Pimavanserin Study</title>
		<link>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307</link>
		<comments>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307#comments</comments>
		<pubDate>Thu, 11 Mar 2010 02:31:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30307</guid>
		<description><![CDATA[Biovail (BVF) and Acadia Pharmaceuticals (ACAD) are moving forward with a 3-pronged strategy for pimavanserin. Acadia plans a phase III trial in Parkinson’s disease psychosis (PDP) and a phase II feasibility study in Alzheimer’s disease psychosis (ADP). Biovail plans a phase III trial with pimavanserin as an adjunctive therapy for schizophrenia. All three programs should be up and running by the third quarter 2010. Management has made a number of changes to the planned third phase III program with pimavanserin PDP that we believe will aid in the success of the trial. Firstly, the trial will test only 40mg pimavanserin vs. placebo in a 1:1 randomization. We remind investors that the previous program had 3 arms at a 2:1 randomization (10mg and 40m vs. placebo). Reducing the randomization to 1:1 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/10/bvf-biovail-and-acadia-pharmaceuticals-continue-forward-with-pimavanserin-study/30307/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Drug Application Gets New Target Date</title>
		<link>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381</link>
		<comments>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381#comments</comments>
		<pubDate>Mon, 01 Mar 2010 22:57:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29381</guid>
		<description><![CDATA[Recently, the U.S. Food and Drug Administration (FDA) announced that inclement weather has forced the agency to delay the review of the new drug application (NDA) of the type II diabetes candidate, exenatide once-weekly. Exenatide once-weekly is co-developed by Alkermes Inc. (ALKS), Eli Lilly (LLY) and Amylin Pharmaceuticals Inc. (AMLN). The U.S. agency has set March 12, 2010 as the new target date. Originally, the FDA was scheduled to decide on the drug by March 5, 2010. In July 2009, the FDA accepted the NDA for the candidate. The NDA was filed by the three companies in May 2009. Exenatide once-weekly is an injectable formulation of Amylin’s Byetta (exenatide). Byetta is an injection administered twice daily. Exenatide once-weekly has enormous market potential in the $13 billion type II diabetes market. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/01/alks-alkermes-drug-application-gets-new-target-date/29381/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Pipeline Announces Good News</title>
		<link>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257</link>
		<comments>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257#comments</comments>
		<pubDate>Wed, 17 Feb 2010 22:40:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28257</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced encouraging topline data from an early-stage study of its candidate of ALKS 37. ALKS 37 is an orally active, peripherally-restricted opioid antagonist having the potential to block the effects of opioid agonists on gastrointestinal motility, commonly termed as opioid-induced constipation (OIC). Alkermes intends to present full results from the early-stage study at a future medical meeting. The randomized, double-blind, placebo-controlled study evaluated the safety, tolerability and pharmacokinetics of a single oral administration of 5 ascending doses of the candidate, ranging from 1 mg to 100 mg, in 40 healthy volunteers. The data revealed the presence of low systemic exposure at doses up to 100 mg. The finding was consistent with prior preclinical studies which showed that ALKS 37 targets the gastrointestinal tract with limited systemic exposure ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/alks-alkermes-pipeline-announces-good-news/28257/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Retains Neutral Recommendation</title>
		<link>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398</link>
		<comments>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398#comments</comments>
		<pubDate>Tue, 09 Feb 2010 03:30:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27398</guid>
		<description><![CDATA[We maintain our Neutral rating on Alkermes, Inc. (ALKS) with a price target of $11.50. Alkermes is a drug delivery biotech company which uses its proprietary specialized drug delivery technologies to develop drugs for the treatment of central nervous system (CNS) disorders, alcoholism and diabetes. Alkermes has two approved products on the market. Its lead product, Risperdal Consta (or simply Consta), was developed for the treatment of schizophrenia and bipolar disorder. The drug is marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes. Alkermes also receives royalty revenues on Consta sales. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). The drug is approved in over 75 countries worldwide and marketed in over 50 countries, but the US is clearly the key ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/08/alks-alkermes-retains-neutral-recommendation/27398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Earnings Comes in Well Ahead of Expectations</title>
		<link>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130</link>
		<comments>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:27:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27130</guid>
		<description><![CDATA[Hospira (HSP) reported strong fourth quarter and full year 2009 results. Earnings per share (EPS) came in at 87 cents, well above the Zacks Consensus Estimate of 70 cents and the year-ago earnings of 78 cents. Revenues recorded a year-over-year increase of 15.5% to $1.1 billion, primarily driven by growth in Specialty Injectable Pharmaceuticals (SIP). However, after taking into account certain charges related to its operations and restructuring initiatives, EPS declined 10.8% to 58 cents. For the full year, the company reported revenues and EPS of $3.9 billion (up 6.9%) and $3.11(up 22.9%), respectively. While SIP revenues increased 20.3% from the year-ago period (at constant exchange rates, CER) to $578.3 million, revenues from the Other Pharma segment increased 4.8% to $197.2 million. The strong growth in the SIP segment was ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/hsp-hospira-earnings-comes-in-well-ahead-of-expectations/27130/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Reports Lower Third Quarter Loss</title>
		<link>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199</link>
		<comments>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199#comments</comments>
		<pubDate>Sat, 06 Feb 2010 01:24:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27199</guid>
		<description><![CDATA[Alkermes Inc. (ALKS) reported a third quarter fiscal 2010 net loss of 3 cents per share (excluding items but including stock based compensation) compared with a loss of 9 cents in the year-ago period (excluding the impact of the termination of the collaboration agreements with Cephalon Inc. (CEPH) for Vivitrol but including stock based compensation). Estimate Revisions Trend Two of the 10 analysts covering the stock for the next quarter raised their earnings estimates over the last 30 days while none moved in the opposite direction. This means that majority of them have not revised their estimates for the next quarter, additionally the revision is marginal. Furthermore, two of the 9 analysts covering the stock for the next fiscal year raised their earnings estimates over the last 30 days while ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/05/alks-alkermes-reports-lower-third-quarter-loss/27199/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2010/01/19/pets-petmed-express-beats-consensus-estimates/25293</link>
		<comments>http://www.stockbloghub.com/2010/01/19/pets-petmed-express-beats-consensus-estimates/25293#comments</comments>
		<pubDate>Tue, 19 Jan 2010 23:54:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25293</guid>
		<description><![CDATA[PetMed Express, Inc. (PETS), America’s largest Pet Pharmacy, recently reported third-quarter fiscal 2010 results. The quarterly earnings of 25 cents a share were above the Zacks Consensus Estimate by 2 cents, and rose 19% year over year from 21 cents posted in the prior-year quarter. Net sales climbed 11.5% to $48.4 million during the quarter. Reorder sales jumped 17% to $37.6 million. New customer additions for the quarter came in at 151,000 compared to 154,000 new customer additions in the year-ago period, down 2%. Advertising spending, which is the prime factor behind the addition of new customers, climbed 6%, while general and administrative expenses declined 2%. Sales over the Internet in the quarter came in at $33.6 million, up 18%. Approximately 70% of PetMed&#8217;s orders were placed online. Gross profit ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/19/pets-petmed-express-beats-consensus-estimates/25293/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Carries Out Restructuring Plan</title>
		<link>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007</link>
		<comments>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007#comments</comments>
		<pubDate>Thu, 14 Jan 2010 22:42:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25007</guid>
		<description><![CDATA[Hospira (HSP) is carrying out its restructuring plans in an attempt to reduce its operating expenses. The company is reducing its workforce by 10% (1400-1500 employees), which would result in savings of $110 -$140 million by 2011. This initiative, named ‘Project Fuel’, was announced by the company earlier in March 2009. Management reiterated the restructuring plan at the recently held JP Morgan Healthcare Conference. The main aim of the project was to optimize the product portfolio, evaluate non-strategic assets and streamline the organizational structure. During the third quarter conference call, management announced that they are on track to meet the milestones, having notified almost 60% of the targeted 1400–1500 positions. In order to hive off the non-strategic assets, in July 2009, Hospira decided to sell its critical care business to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/14/hsp-hospira-carries-out-restructuring-plan/25007/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Nektar Therapeutics Announces Preliminary Data</title>
		<link>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879</link>
		<comments>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879#comments</comments>
		<pubDate>Thu, 14 Jan 2010 00:31:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24879</guid>
		<description><![CDATA[Recently, Nektar Therapeutics (NKTR) announced preliminary results from the first stage of phase II study of its experimental ovarian cancer drug, NKTR-102. It has been observed that the drug, tested in women with platinum-resistant ovarian cancer, achieved an overall response rate of 32% and 35% in two dosage schedules – once every 14 days and once every 21 days. Common side effects such as diarrhea and neutropenia were observed during the trial. Nektar announced that enrollment of patients ? 71 in all ? in the trial has been completed. Apart from ovarian cancer, NKTR-102 is also being studied in two other mid-stage trials for the treatment of metastatic breast cancer and second-line colorectal cancer. We believe favorable data from the phase II trial could enable Nektar to enter into suitable ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/13/nktr-nektar-therapeutics-announces-preliminary-data/24879/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Small-Cap Biotech Stocks: Why This Sector Is Set for a Huge Year</title>
		<link>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311</link>
		<comments>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311#comments</comments>
		<pubDate>Thu, 07 Jan 2010 00:12:43 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24311</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, January 6, 2010: Issue #1169 Now that we’re into the first week of 2010, let’s talk about the Super Bowl. But not the one in Miami, featuring a bunch of guys with pads and helmets. I’m talking about the healthcare sector’s version of the Super Bowl, taking place on the other side of the United States next week. On Sunday, I’ll be boarding a plane and escaping from the frozen tundra that is South Florida these days (seriously, 29 degrees last night) and on my way to San Francisco for the J.P. Morgan Healthcare Conference. And just like the Super Bowl, tickets for the conference are extremely hard to get. It’s the most important healthcare conference of the year, and roughly 14,000 investors and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/nktr-small-cap-biotech-stocks-why-this-sector-is-set-for-a-huge-year/24311/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Aquires Pharmaceuticals Business</title>
		<link>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996</link>
		<comments>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996#comments</comments>
		<pubDate>Wed, 16 Dec 2009 23:10:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=22996</guid>
		<description><![CDATA[Hospira (HSP) has been making certain strategic moves in the recent past; the latest deal will establish its presence in one of the most sought after emerging market ? India. Hospira decided to acquire India-based Orchid Chemicals’ generic injectable finished-dosage form pharmaceuticals business for approximately $400 million. The transaction, expected to be completed by the first quarter of 2010, will be EPS neutral for Hospira in 2010, excluding the associated costs. The acquisition involves Orchid&#8217;s beta-lactam antibiotics (a class of drugs with a wide spectrum of antibacterial activity) manufacturing complex (comprising cephalosporin, penicillin and carbapenem facilities) and pharmaceutical research and development (R&#38;D) facility at Irungattukottai, Chennai, as well as its generic injectable product portfolio and pipeline. The manufacturing site has necessary approvals from international regulatory authorities Incorporatedluding the US Food ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/16/hsp-hospira-aquires-pharmaceuticals-business/22996/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861</link>
		<comments>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861#comments</comments>
		<pubDate>Wed, 18 Nov 2009 22:51:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20861</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its drug Vivitrol, which is indicated for the treatment of alcohol dependence, also helped opioid addicts stay away from drugs. Data from the six-month late-stage trial (n=250) demonstrated that subjects injected with Vivitrol (naltrexone for extended-release injectable suspension) once a month were more likely to pass a urine test compared to recipients of a placebo injection. Furthermore, subjects reported a lower craving for drugs, and half the subjects came clean in at least 90% of their drug tests. The subjects were addicted to opioid drugs including heroin. Before enrolling for the trial, they had to stay away from drugs for at least a week. The most common adverse event affecting patients during the study were inflammation of the nose and throat in addition to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/18/alks-good-news-for-alkermes-drug-pipeline-2/20861/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Moves to Loss but Beats Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142</link>
		<comments>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142#comments</comments>
		<pubDate>Tue, 10 Nov 2009 00:15:45 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20142</guid>
		<description><![CDATA[Alkermes, Inc. (ALKS) reported a second quarter fiscal 2010 net loss of 5 cents per share, compared with a profit of 2 cents in the year-ago period. The Zacks Consensus Estimate was a loss of 10 cents. Revenues in the quarter increased 1.9 % to $48.2 million from $47.3 million in the year-ago quarter. The increase was driven by manufacturing and royalty revenues from Risperdal Consta. Total manufacturing revenues for the quarter came in at $32.8 million as against $33 million in the year-ago quarter.  Manufacturing revenues for the quarter included $31.9 million related to Risperdal Consta, marketed worldwide by Johnson &#38; Johnson (JNJ) and manufactured by Alkermes, compared to $30.7 million for Consta and $2.3 million for Vivitrol for the year-ago quarter. Royalty revenues for the quarter came in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/09/alks-alkermes-moves-to-loss-but-beats-consensus-estimates/20142/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) The F.I.R.S.T. System: Searching For the “Holy Grail” of Investing</title>
		<link>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084</link>
		<comments>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084#comments</comments>
		<pubDate>Wed, 28 Oct 2009 21:37:38 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19084</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, October 28, 2009: Issue #1125 When it comes to investing, how do you find the “Holy Grail?” Does it even exist? Over my 19 years of stock market experience, I’ve searched high and low for the answers. One of my first steps was to plow into technical analysis. I studied everything I could, believing that charts could predict a stock’s direction. I even became a trained technician, finishing two out of the three exams required to be a Chartered Market Technician. I never took the third. While I believe technical analysis is useful, it didn’t provide the answers I was looking for. In 2005, Avalon Research Group hired me as a fundamental analyst. While at Avalon, I worked with two of the greatest contrarians ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/28/nktr-the-f-i-r-s-t-system-searching-for-the-%e2%80%9choly-grail%e2%80%9d-of-investing/19084/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Surges Ahead</title>
		<link>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936</link>
		<comments>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936#comments</comments>
		<pubDate>Wed, 28 Oct 2009 03:49:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[MAXIMUS Inc.]]></category>
		<category><![CDATA[MMS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18936</guid>
		<description><![CDATA[Hospira (HSP) reported third quarter earnings of 90 cents per share, well above both the Zacks Consensus Estimate of 68 cents and 63 cents per share in the year-ago period. Revenues increased 8.9% to $1 billion, primarily driven by growth in Specialty Injectable Pharmaceuticals (SIP). SIP revenues increased 25.6% from the year-ago period (at constant exchange rates, CER) to $575.7 million while revenues from the Other Pharma segment came down 8.4% to $157.4 million. The strong growth in the SIP segment was driven by the launch of the generic oncolytic oxaliplatin in the quarter. Unlike the previous quarter, revenues from Medication Management Systems (MMS) increased 1.7% year over year at CER to $162.6 million. However, Other Devices continued to fall in the reported quarter and recorded revenues of $111.8 million, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/hsp-hospira-surges-ahead/18936/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PETS) PetMed Express In-Line with Consensus Estimates</title>
		<link>http://www.stockbloghub.com/2009/10/21/pets-petmed-express-in-line-with-consensus-estimates/18375</link>
		<comments>http://www.stockbloghub.com/2009/10/21/pets-petmed-express-in-line-with-consensus-estimates/18375#comments</comments>
		<pubDate>Wed, 21 Oct 2009 23:51:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[PetMed Express Inc.]]></category>
		<category><![CDATA[PETS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18375</guid>
		<description><![CDATA[PetMed Express, Inc. (PETS), the America ’s largest Pet Pharmacy, recently reported second-quarter 2010 results. The quarterly earnings of 28 cents a share came in line with the Zacks Consensus Estimate but rose 12% year-on-year from 25 cents posted in the prior-year quarter. Net sales climbed 5% to $62.4 million during the quarter. Reorder sales jumped 11% to $45.8 million, whereas new order sales fell 8% to $16.7 million, as the new customer additions fell 3% to 233,000 due to lower advertising spending (down 10% to $7.8 million). However, the cost to acquire a new customer fell 8% to $33 from $36 in the year-ago quarter. PetMed also notified that the average order size for the quarter fell to $78 from $81 in the prior-year quarter due to customers purchasing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/21/pets-petmed-express-in-line-with-consensus-estimates/18375/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Good News for Alkermes&#8217; Drug Pipeline</title>
		<link>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689</link>
		<comments>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689#comments</comments>
		<pubDate>Fri, 16 Oct 2009 22:57:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17689</guid>
		<description><![CDATA[Recently, Alkermes Inc. (ALKS) announced that its pipeline candidate, ALKS33, for addiction and nervous system disorders, gave positive results in two early stage clinical trials. Results from the two studies, ALK33-003 and ALK33-004, demonstrated that the candidate blocked the effects of an opioid with an action duration that supported once daily dosing. The studies were initiated in May this year. ALK33-003, a randomized, double-blind, placebo-controlled, multi-dose study, evaluated the pharmacokinetics, safety and tolerability of multiple doses of ALKS33 in 30 healthy volunteers. ALK33-004, a randomized, single-blind, placebo-controlled, single-dose study, was designed to examine the ability of ALKS33 to block the effects of an opioid following a single oral dose of ALKS33 in 24 healthy, non-dependent, opioidexperienced subjects. ALKS33, an oral opioid modulator, was generally well-tolerated in both the studies. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/alks-good-news-for-alkermes-drug-pipeline/17689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BVF) Biovail Corporation Continues with Pimavanserin</title>
		<link>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694</link>
		<comments>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694#comments</comments>
		<pubDate>Fri, 16 Oct 2009 21:49:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACAD]]></category>
		<category><![CDATA[ACADIA Pharmaceuticals Inc]]></category>
		<category><![CDATA[ADP]]></category>
		<category><![CDATA[Automatic Data Processing Inc]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>
		<category><![CDATA[PDP]]></category>
		<category><![CDATA[PowerShares DWA Technical Leaders]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17694</guid>
		<description><![CDATA[Biovail Corporation (BVF) recently provided an update on its development plans for pimavanserin for Parkinson’s disease psychosis (PDP). The company is developing the candidate in collaboration with Acadia Pharmaceuticals, Inc. (ACAD) and stated that the partners remain committed towards the successful development of the candidate. In early Sept. 2009, the companies had reported results from a pivotal phase III study (-012 study) in which pimavanserin failed to meet its primary endpoint of antipsychotic efficacy due to an unexpectedly high placebo response rate. Based on an analysis of the data from this study, the partners have decided to continue with the development of the candidate. The companies intend to use findings from the -012 study and an ongoing phase III study (-014 study) for a new phase III trial. The new ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/bvf-biovail-corporation-continues-with-pimavanserin/17694/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ELN) SEC Subpoena for Elan Regarding Tysabri Use Disclosure</title>
		<link>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607</link>
		<comments>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607#comments</comments>
		<pubDate>Wed, 14 Oct 2009 15:31:01 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17607</guid>
		<description><![CDATA[Elan Corporation (ELN) recently received a subpoena from the US Securities and Exchange Commission (SEC) regarding the company’s disclosure of two brain disorder cases (in July 2008), often fatal, tied to the use of its drug Tysabri for the treatment of multiple sclerosis. Elan has a marketing agreement with Biogen Idec (BIIB) for Tysabri. In addition, the subpoena asked for detailed information regarding clinical trial data on bapineuzumab, a drug for the treatment of Alzheimer&#8217;s disease. Recently, Johnson &#38; Johnson (JNJ) paid $885 million for an 18.4% stake in Elan in addition to $500 million for a majority stake in the company’s Alzheimer&#8217;s disease pipeline. As a reminder, in July last year, both Elan and Biogen announced the occurrence of two cases of brain infection, progressive multifocal leukoencephalopathy [PML], in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/14/eln-sec-subpoena-for-elan-regarding-tysabri-use-disclosure/17607/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NKTR) Nektar Therapeutics Presents Favorable Phase II Trial Data</title>
		<link>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491</link>
		<comments>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491#comments</comments>
		<pubDate>Tue, 13 Oct 2009 19:35:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Nektar Therapeutics]]></category>
		<category><![CDATA[NKTR]]></category>
		<category><![CDATA[WYE]]></category>
		<category><![CDATA[Wyeth]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17491</guid>
		<description><![CDATA[Recently, Nektar Therapeutics (NKTR) presented data from its phase II trial of oral NKTR-118, meant for the treatment of opioid-induced constipation. The data was presented at the American Academy of Pain Management&#8217;s 20th Annual Clinical Meeting in Phoenix, AZ. The drug met the primary endpoint of increase in spontaneous bowel movement over the baseline period along with no reduction of opioid-mediated analgesia in any dose groups. In addition, NKTR-118 was well tolerated, the common side effects being dose-dependent gastrointestinal-related effects. In September, AstraZeneca (AZN) had entered into a licensing deal with Nektar Therapeutics for two of its pipeline candidates, NKTR-118 and NKTR-119. While the former is a phase II trial candidate, the latter, in its early stage of development, is intended to treat pain without constipation as a side effect. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/13/nktr-nektar-therapeutics-presents-favorable-phase-ii-trial-data/17491/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(HSP) Hospira Ups 2009 Earnings Guidance</title>
		<link>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523</link>
		<comments>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523#comments</comments>
		<pubDate>Sat, 03 Oct 2009 21:42:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BAX]]></category>
		<category><![CDATA[Baxter International Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=16523</guid>
		<description><![CDATA[Lake Forest, Illinois-based specialty pharmaceutical products maker Hospira (HSP) recently raised its 2009 outlook. The company now sees earnings in the range of $2.80 to $2.85 per share up from its earlier guidance of $2.70 to $2.75. Annual revenue is expected to rise by 5 to 7% compared to the earlier expected growth of 4 to 6% on a constant currency basis. Hospira also boosted its 2009 outlook for gross margin, operating margin and cash flow from operations to 39.5%-40.5%, 18%-19% and $610 million-$660 million, respectively. Hospira said it is confident that its cost-cutting and restructuring initiative, Project Fuel, would improve profitability through 2011. The company’s restructuring plan consists of a 10% reduction in workforce and realignment of its product portfolio including the sale of non-core businesses. It has already ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/03/hsp-hospira-ups-2009-earnings-guidance/16523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Alkermes Notified Johnson &amp; Johnson Intends to Stop Development of Risperidone</title>
		<link>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717</link>
		<comments>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717#comments</comments>
		<pubDate>Thu, 27 Aug 2009 23:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13717</guid>
		<description><![CDATA[On Wednesday, Alkermes, Inc. (ALKS) disclosed that it has received notification from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International stating that Janssen does not intend to continue with the development of the four-week long-acting injectable formulation of risperidone. A phase I study with the four-week formulation had been initiated in January 2009. Risperidone, which is marketed as Risperdal Consta, is Alkermes’ lead product. Risperdal Consta is the longer-lasting injectable version of Johnson &#38; Johnson&#8217;s schizophrenia drug Risperdal (risperidone). Risperdal Consta uses Alkermes&#8217; proprietary Medisorb technology to deliver and maintain therapeutic medication levels in the body through just one injection every two weeks. The product is approved in more than 85 countries worldwide and is available in 60 countries. Risperdal Consta is superior to the first-generation Risperdal ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/alks-alkermes-notified-johnson-johnson-intends-to-stop-development-of-risperidone/13717/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BVF) Biovail Agreed to Develop Parkinson&#8217;s Drug</title>
		<link>http://www.stockbloghub.com/2009/08/24/bvf-biovail-agreed-to-develop-parkinsons-drug/13213</link>
		<comments>http://www.stockbloghub.com/2009/08/24/bvf-biovail-agreed-to-develop-parkinsons-drug/13213#comments</comments>
		<pubDate>Mon, 24 Aug 2009 21:07:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biovail Corporation]]></category>
		<category><![CDATA[BVF]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13213</guid>
		<description><![CDATA[Biovail Corp. (BVF) today agreed to buy US and Canadian rights to develop and market JP-1730/fipamezole for the treatment of Dyskinesia in Parkinson&#8217;s Disease (DPD) from Santhera Pharmaceuticals. According to the deal, Biovail will make an upfront payment of $8 million and another $4 million after successful closing of Santhera&#8217;s acquisition of Oy Juvantia Pharma Ltd. Additionally, the company will also pay up to $35 million associated with the potential development and regulatory milestones for the initiation of a late-stage study, regulatory submissions and approvals of JP-1730/fipamezole in DPD. Biovail will make milestone payments of up to $145 million on achievement of certain sales target. It has to pay royalties of 8% to 15% on net commercial sales of the drug. If the company chooses to pursue a second indication, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/bvf-biovail-agreed-to-develop-parkinsons-drug/13213/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

